| 1 |
35409939 | Predicting Response to Anthracyclines in Ovarian Cancer. | 2022 Apr 2 |
1 |
| 2 |
34282771 | TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. | 2021 Jul 5 |
1 |
| 3 |
31119730 | Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. | 2020 Jan 15 |
1 |
| 4 |
32992248 | Structural basis for stabilization of human telomeric G-quadruplex [d-(TTAGGGT)]4 by anticancer drug epirubicin. | 2020 Dec 1 |
1 |
| 5 |
33244272 | Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer. | 2020 |
1 |
| 6 |
30728290 | Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity. | 2019 Feb 6 |
2 |
| 7 |
31075046 | Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE). | 2019 Jul 1 |
1 |
| 8 |
31441737 | [Prognostic role of p53 gene polymorphism in risk assessment of anthracycline-induced cardiotoxicity]. | 2019 Aug 22 |
1 |
| 9 |
29983877 | Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells. | 2018 Jun 19 |
9 |
| 10 |
27888811 | The role of p53 in cancer drug resistance and targeted chemotherapy. | 2017 Jan 31 |
1 |
| 11 |
28179588 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. | 2017 Mar 14 |
1 |
| 12 |
28714573 | Assessment of the DNA damaging potential of environmental chemicals using a quantitative high-throughput screening approach to measure p53 activation. | 2017 Aug |
1 |
| 13 |
26238069 | TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer. | 2016 Jan 15 |
2 |
| 14 |
27611952 | Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. | 2016 Oct 18 |
2 |
| 15 |
27708748 | Prevalence of the CHEK2 R95* germline mutation. | 2016 |
1 |
| 16 |
25698149 | p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. | 2015 Jun |
1 |
| 17 |
25713207 | Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells. | 2015 May |
1 |
| 18 |
25750340 | Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance. | 2015 Mar |
1 |
| 19 |
26004085 | Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. | 2015 Oct |
1 |
| 20 |
25051299 | Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. | 2014 Oct |
1 |
| 21 |
23246812 | Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. | 2013 Mar |
3 |
| 22 |
23804139 | p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer. | 2013 |
1 |
| 23 |
23897043 | Validation of a yeast functional assay for p53 mutations using clonal sequencing. | 2013 Dec |
1 |
| 24 |
22420423 | Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. | 2012 Mar 15 |
4 |
| 25 |
22549273 | Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group. | 2012 Oct |
2 |
| 26 |
22551440 | Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. | 2012 May 2 |
3 |
| 27 |
21441950 | Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms. | 2011 Aug 18 |
4 |
| 28 |
21556366 | Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. | 2011 Apr 27 |
1 |
| 29 |
22233820 | Relationship between thymidylate synthase and p53 and response to FEC versus taxane adjuvant chemotherapy for breast carcinoma. | 2011 Dec |
1 |
| 30 |
20038740 | Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. | 2010 Jan 19 |
1 |
| 31 |
20228131 | Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. | 2010 |
3 |
| 32 |
20662736 | Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. | 2010 Aug |
1 |
| 33 |
19265549 | Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. | 2009 Mar 5 |
1 |
| 34 |
19304743 | p53 as a specific prognostic factor in triple-negative breast cancer. | 2009 Apr |
2 |
| 35 |
19828073 | Conditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers. | 2009 Oct 15 |
1 |
| 36 |
18325917 | p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. | 2008 Jul |
3 |
| 37 |
18510179 | Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients. | 2008 Mar |
1 |
| 38 |
17369602 | p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. | 2007 Jun |
1 |
| 39 |
16720917 | Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. | 2006 |
1 |
| 40 |
16766179 | Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. | 2006 Jul |
2 |
| 41 |
18528466 | The individualization of cancer therapy: the unexpected role of p53. | 2006 |
1 |
| 42 |
15456408 | PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. | 2005 Feb 15 |
1 |
| 43 |
15940066 | Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. | 2005 May |
1 |
| 44 |
16159878 | Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. | 2005 Dec 2 |
1 |
| 45 |
16243804 | p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. | 2005 Oct 15 |
1 |
| 46 |
15138567 | Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. | 2004 Jun |
1 |
| 47 |
15763945 | Differential toxicity of anthracyclines on cultured endothelial cells. | 2004 Sep-Dec |
1 |
| 48 |
12751374 | A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. | 2003 Mar |
3 |
| 49 |
12853365 | p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with anthracycline-containing regimens. | 2003 Jul |
1 |
| 50 |
14654539 | TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. | 2003 Nov 15 |
2 |